Marketing - Press Releases

Date	Title	Company
09-Dec-2019	Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®	UCB
09-Dec-2019	ReNeuron Group plc - Interim Results	ReNeuron Group plc
09-Dec-2019	Professor Amit Nathwani will present the Ham-Wasserman Lecture at the 61st ASH Annual Meeting	Freeline
09-Dec-2019	BC Platforms Partners with leading European Genomics Service Provider Life & Brain to Expand Genotyping Services Across Europe	BC Platforms
09-Dec-2019	UKCPA publish recommendations to avoid errors with Syntocinon® & Syntometrine®	UKCPA
09-Dec-2019	Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®	UCB
09-Dec-2019	ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available	ViiV Healthcare
09-Dec-2019	Takeda and Enzyre to develop diagnostic device allowing hemophilia patients to determine their coagulation status at home	Takeda Pharmaceutical Company Limited
09-Dec-2019	PureTech Affiliate Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections	PureTech Health plc
09-Dec-2019	HUMMINGBIRD BIOSCIENCE RAISES US$19 MILLION IN SERIES B FINANCING	Hummingbird Bioscience
09-Dec-2019	PHASTAR Gains 2020 ‘Best Companies’ Accreditation for Employee Engagement	PHASTAR
09-Dec-2019	Orgenesis launches Point of Care cell and gene therapy centers within HYGEIA Group’s Greek hospital network	HYGEIA Group
09-Dec-2019	Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis	Galderma
09-Dec-2019	Gelesis Secures Over $84 Million in New Capital to Support Commercialization of PLENITY™	Gelesis
09-Dec-2019	Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors	Nouscom
09-Dec-2019	HVIVO (“HVIVO”) to merge with OPEN ORPHAN PLC (“OPEN ORPHAN”)	The Boards of Open Orphan and hVIVO
09-Dec-2019	Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the treatment of onychomycosis	Moberg Pharma AB
06-Dec-2019	Onyx Health Celebrate ‘Historic Year’ with New Appointments and Double-Digit Growth	Onyx Health
06-Dec-2019	Key Objectives of The Medical Device and In-Vitro Diagnostic Regulations	PharmaLex
06-Dec-2019	Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen	Genmab